• Fujiao Duan, Kaijuan Wang, Liping Dai, Xia Zhao, Yajing Feng, Chunhua Song, Shuli Cui, and Chengzeng Wang.
• Department of Hospital Infection Management Department of Ultrasound, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China Department of Epidemiology, College of Public Health, Zhengzhou University Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, Henan, China College of Professional Study, Northeastern University, Boston, MA.
• Medicine (Baltimore). 2016 Sep 1; 95 (37): e4773e4773.

BackgroundMounting evidence showed that microRNAs may be useful as prognostic biomarkers of cancer. Therefore, we summarize the predictive role of microRNA-218 (miR-218) for survival in patients with various cancers.MethodsWe performed a systematic literature review and assessed the quality of included studies based on Meta-analysis of Observational Studies in Epidemiology group (MOOSE). Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the correlation between miR-218 expression and prognosis of different cancers.ResultsWe identified 10 studies for pooled analyses. For overall survival, a lower expression levels of miR-218 significantly predicted poorer survival, with the pooled HR of 2.61 (95% CI: 2.11-3.22, P < 0.001). For disease-free survival/progressive-free survival/recurrence-free survival (DFS/PFS/RFS), a lower expression level of miR-218 significantly predicted worse DFS/PFS/RFS in various carcinomas, with the pooled HR of 2.73 (95% CI: 2.08-3.58, P < 0.001). Similarly, subgroup analysis by detection method, ethnicity and cancer subtype analysis suggested that lower expression of miR-218 correlated with.ConclusionOur data demonstrated that lower miR-218 expression is significantly associated with poorer overall survival (OS) and DFS/PFS/RFS and may be a novel prognostic biomarker in some cancer types.

10 keywords...

hide…